Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
Adithya Hande, Head of Clinical Projects at DERBI Foundation, shared a post on LinkedIn:
”India’s Silent Killer — and a Scientific Breakthrough You Need to Know About
Thrombosis-related diseases (like pulmonary embolism, stroke, and DVT) are quietly responsible for millions of hospitalizations and deaths in India each year — especially post-COVID.
Yet, we’re still relying on decades-old anticoagulants with dangerous side effects like internal bleeding and poor patient adherence.
But what if we could prevent clots safely, without disrupting the body’s natural healing?
Scientists at IISc have developed a game-changing nanozyme that mimics antioxidant enzymes — a first-of-its-kind, bleeding-free clot therapy.
This article dives into:
- What makes this science revolutionary
- The current treatment challenges for thrombosis in India
- Market gaps ripe for startup innovation
- Why this could be a deeptech goldmine for healthcare entrepreneurs
Click below to read the full breakdown — from a healthcare innovation lens.”
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25
-
Jan 7, 2026, 05:04Heghine Khachatryan on VWD: A Landmark in the History of Hematology
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications